{"id":"NCT00872170","sponsor":"Carelon Research","briefTitle":"Sildenafil to Improve Exercise Capacity in People With Thalassemia and Pulmonary Hypertension","officialTitle":"Pilot of Oral Sildenafil for the Treatment of Pulmonary Hypertension in Thalassemia With Comparison to Controls","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2009-03","primaryCompletion":"2010-06","completion":"2010-11","firstPosted":"2009-03-31","resultsPosted":"2014-02-21","lastUpdate":"2014-02-21"},"enrollment":27,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Thalassemia","Hypertension, Pulmonary"],"interventions":[{"type":"DRUG","name":"Sildenafil","otherNames":["Revatio","Viagra"]}],"arms":[{"label":"Intervention","type":"ACTIVE_COMPARATOR"},{"label":"Control","type":"NO_INTERVENTION"}],"summary":"Thalassemia is an inherited blood disorder that can result in mild to severe anemia. Many people with thalassemia also have pulmonary hypertension, which is high blood pressure in the arteries in the lungs. This study will evaluate the safety and effectiveness of the medication sildenafil at reducing blood pressure in the lungs of people with thalassemia and pulmonary hypertension.","primaryOutcome":{"measure":"Change in Six-minute Walk Test (6MWT) Distance From Baseline to Week 12 Among Sildenafil Group","timeFrame":"Baseline and Week 12","effectByArm":[{"arm":"Sildenafil","deltaMin":-1.38,"sd":16.01}],"pValues":[{"comp":"OG000","p":"0.97"}]},"eligibility":{"minAge":"7 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":5},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["23585527"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":14},"commonTop":["Headache","Vision/color disturbance","Edema limbs","Dyspnea","Fatigue"]}}